Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 6;12(3):615. doi: 10.3390/cancers12030615

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Haprolid treatment inhibits tumor spheroids growth and invasion and partially impairs epithelial–mesenchymal transition (EMT) in human HCC cells. (A) Three-dimensional tumor spheroid assay was performed to evaluate effects of haprolid on HCC cell proliferative and invasive ability in extracellular-matrix-like environment. The representative images of spheroids are shown. The changes of spheroids size were monitored and quantified up to 10 days and plotted in bar graphs. (B) Hep3B and Huh-7 cells were treated with DMSO or haprolid (0.06, 0.6 and 6 µg/mL) for 96 h. The expressions of EMT markers (N-cadherin, E-cadherin, vimentin and Snail) were analyzed by immunoblotting. Western blotting bands were quantified by Image J and normalized to their respective β-actin then compared with vehicle-treated controls. Data represent means ± SEM of at least three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Haprolid treatment inhibits tumor spheroids growth and invasion and partially impairs epithelial–mesenchymal transition (EMT) in human HCC cells. (A) Three-dimensional tumor spheroid assay was performed to evaluate effects of haprolid on HCC cell proliferative and invasive ability in extracellular-matrix-like environment. The representative images of spheroids are shown. The changes of spheroids size were monitored and quantified up to 10 days and plotted in bar graphs. (B) Hep3B and Huh-7 cells were treated with DMSO or haprolid (0.06, 0.6 and 6 µg/mL) for 96 h. The expressions of EMT markers (N-cadherin, E-cadherin, vimentin and Snail) were analyzed by immunoblotting. Western blotting bands were quantified by Image J and normalized to their respective β-actin then compared with vehicle-treated controls. Data represent means ± SEM of at least three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.